Tepilukimig
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research[1][2].
Product Specifications
CAS Number
2985643-31-8
UNSPSC
12352100
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Field of Research
Inflammation/Immunology
References & Citations
[1]Smolinska S, et al. Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma. Int J Mol Sci. 2023 Aug 12;24 (16) :12725.|[2]Internacionales D C. International Nonproprietary Names for Pharmaceutical Substances (INN) [J]. WHO Drug Information, 2025, 39 (2) .
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
IL-7
More Discoveries
Explore Other Products
Browse additional items from our catalog
